nach oben

Current Hematologic Malignancy Reports

Erschienen in:

01.12.2011 | T-Cell and Other Lymphoproliferative Malignancies (Claire Dearden, Section Editor)

PET in T-Cell Lymphoma

verfasst von: Pier Luigi Zinzani

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18]fluoro-2-deoxy-D-glucose (18FDG) uptake varies among different subtypes of lymphoma, a disparity that can be explained by the differences in histology, proliferation of tumor cells, and the ratio of viable tumor and reactive cells in the environment. These observations are based on investigation of B-cell lymphomas. Positron emission tomography (PET)/computed tomography (CT) was found to be useful both at staging and at measuring the therapeutic outcome after two to three cycles of chemotherapy (interim PET/CT). Several meta-analyses have confirmed the role of PET in evaluating the viability of the residual tumor mass after treatment. 18FDG-PET has been proved to have an excellent negative predictive value. Conversely, only a few studies have investigated the role of FDG-PET in T/NK-cell lymphomas. This paper summarizes the current information regarding the potential use of PET/CT in patients with T-cell lymphoma.

Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1.PubMed

Jerusalem G, Warland V, Najjar F, et al. Whole-body 18 F-FDG PET for the evaluation of patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Nucl Med Commun. 1999;20:13–20.PubMedCrossRef

Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine- 18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 2001;91:889–99.PubMedCrossRef

Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47:1643–8.PubMed

Kwee TC, Kwee RM, Nievelstein RA. Imaging in stagin of malignant lymphoma: a systematic review. Blood. 2008;111:504–16.PubMedCrossRef

Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol. 2001;12:825–30.PubMedCrossRef

Bangerter M, Moog F, Buchmann I, et al. Whole-body 2- [18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol. 1998;9:1117–22.PubMedCrossRef

Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica. 2001;86:266–73.PubMed

Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematol. 2002;81:20–5.PubMedCrossRef

10.

Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin’s lymphoma. Br J Cancer. 2004;90:620–5.PubMedCrossRef

11.

Newman JS, Francis JR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-Dglucose: correlation with CT. Radiology. 1994;190:111–6.PubMed

12.

Thill R, Neuerburg J, Fabry U, et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin. 1997;36:234–9.PubMed

13.

Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875–6.PubMedCrossRef

14.

Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) and a comparison of 18FFDG- PET with 67gallium scintigraphy in the evaluation of lymphoma. Relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652–9.PubMedCrossRef

15.

• Khong P-L, Pang CBY, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008;87:613–21. This article presents interesting data on the role of PET scans in mature T-cell and NK-cell malignancies.

16.

• Berk V, Yildiz R, Akdemir UO, et al. Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules. Utility of 18F-FDG PET in staging. Clin Nucl Med. 2008;33:365–6. This article presents an evaluation of PET scans in rating T-cell disorders.

17.

Kako S, Izutsu K, Ota Y, et al. FDG PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18:1685–90.PubMedCrossRef

18.

Suh C, Kang Y-K, Roh J-L, et al. Prognostic value of tumor 18F-FDG uptake in patients with untreated exranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med. 2008;49:1783–9.PubMedCrossRef

19.

Horwitz SM, Foss F, Goldfarb S, et al. FDG-PET scans as a staging study for T-cell lymphomas: high rates of positivity do not result in frequent changes in stage. Blood. 2006;108:679a. abstract 2399.

20.

Karantanis D, Subramanium RM, Peller PJ, et al. The value of [18F] fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma. 2008;8:94–9.PubMedCrossRef

21.

Hadithi M, Mallant M, Oudejans J, et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med. 2006;47:1622–7.PubMed

22.

Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med. 1994;8:187–91.PubMedCrossRef

23.

Watanabe N, Murakami J, Kameda K, et al. F-18 FDGPET imaging in adult T-cell leukemia lymphoma. Clin Nucl Med. 2008;33:423–5.PubMedCrossRef

24.

Shapiro M, Yun M, Junkins-Hopkins JM, et al. Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. J Amer Acad Dermatol. 2002;47:623–8.CrossRef

25.

Hoffmann M, Vogelsang H, Kletter K, et al. 18F-fluorodeoxy- glucose positron emission tomography (18FFDG- PET) for assessment of enteropathy-type T cell lymphoma. Gut. 2003;52:347–51.PubMedCrossRef

26.

• Kuo PH, McClennan BL, Carlson K, et al. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imaging Biol. 2008;10:74–81. This article compares PET and CT scans in the evaluation of patients with cutaneous T-cell lymphoma.

27.

Tsai EY, Taur A, Espinosa L, et al. Staging accuracy in mycosis fungoides and Sézary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol. 2006;142:577–84.PubMedCrossRef

28.

Kumar R, Xiu Y, Zhuang HM, et al. 18F-fluorodeoxyglucose- positron emission tomography in evaluation of primary cutaneous lymphoma. Br J Dermatol. 2006;155:357–63.PubMedCrossRef

29.

Kuo PH, Carlson KR, Christensen I, et al. FDG-PET/CT for the evaluation of response to therapy of cutaneous Tcell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial. Mol Imaging Biol. 2008;10:306–14.PubMedCrossRef

30.

Gallamini A, Rigaci L, Merli F, et al. Predictive value of positron emission tomography performer after two coureses of standard therapy on treatment out come in advanced stage Hodgkin’s disease. Haematologica. 2006;91:475–81.PubMed

31.

Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol. 2006;17:1296–300.PubMedCrossRef

32.

Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F] fluoro-2-D-glucose positron emission tomography is prognostically superior to International prognostic score in advanced stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.PubMedCrossRef

Titel: PET in T-Cell Lymphoma
verfasst von: Pier Luigi Zinzani
Publikationsdatum: 01.12.2011
Verlag: Current Science Inc.
Erschienen in: Current Hematologic Malignancy Reports / Ausgabe 4/2011
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-011-0098-6

Springer Medizin

PET in T-Cell Lymphoma

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Rituximab Maintenance Versus Radioimmunotherapy Consolidation in Follicular Lymphoma: Which, When, and for Whom?

CD30+ Neoplasms of the Skin

Update: Peripheral T-Cell Lymphomas

Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Clinical Features, and Current Treatment Strategies

Recent Developments in Nongastric Mucosa-Associated Lymphoid Tissue Lymphoma

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie